Literature DB >> 28330929

The Role of PIAS SUMO E3-Ligases in Cancer.

Andrea Rabellino1,2,3, Cristina Andreani1,2, Pier Paolo Scaglioni4,2.   

Abstract

SUMOylation modifies the interactome, localization, activity, and lifespan of its target proteins. This process regulates several cellular machineries, including transcription, DNA damage repair, cell-cycle progression, and apoptosis. Accordingly, SUMOylation is critical in maintaining cellular homeostasis, and its deregulation leads to the corruption of a plethora of cellular processes that contribute to disease states. Among the proteins involved in SUMOylation, the protein inhibitor of activated STAT (PIAS) E3-ligases were initially described as transcriptional coregulators. Recent findings also indicate that they have a role in regulating protein stability and signaling transduction pathways. PIAS proteins interact with up to 60 cellular partners affecting several cellular processes, most notably immune regulation and DNA repair, but also cellular proliferation and survival. Here, we summarize the current knowledge about their role in tumorigenesis and cancer-related processes. Cancer Res; 77(7); 1542-7. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28330929      PMCID: PMC5380518          DOI: 10.1158/0008-5472.CAN-16-2958

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Authors:  Andrea Rabellino; Brandon Carter; Georgia Konstantinidou; Shwu-Yuan Wu; Alessandro Rimessi; Lauren A Byers; John V Heymach; Luc Girard; Cheng-Ming Chiang; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

2.  Pias1 is essential for erythroid and vascular development in the mouse embryo.

Authors:  Jerfiz D Constanzo; Mi Deng; Smita Rindhe; Ke-Jing Tang; Cheng-Cheng Zhang; Pier Paolo Scaglioni
Journal:  Dev Biol       Date:  2016-05-04       Impact factor: 3.582

3.  A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.

Authors:  Jessica D Kessler; Kristopher T Kahle; Tingting Sun; Kristen L Meerbrey; Michael R Schlabach; Earlene M Schmitt; Samuel O Skinner; Qikai Xu; Mamie Z Li; Zachary C Hartman; Mitchell Rao; Peng Yu; Rocio Dominguez-Vidana; Anthony C Liang; Nicole L Solimini; Ronald J Bernardi; Bing Yu; Tiffany Hsu; Ido Golding; Ji Luo; C Kent Osborne; Chad J Creighton; Susan G Hilsenbeck; Rachel Schiff; Chad A Shaw; Stephen J Elledge; Thomas F Westbrook
Journal:  Science       Date:  2011-12-08       Impact factor: 47.728

4.  SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane.

Authors:  Jian Huang; Jie Yan; Jian Zhang; Shiguo Zhu; Yanli Wang; Ting Shi; Changhong Zhu; Cheng Chen; Xin Liu; Jinke Cheng; Tomas Mustelin; Gen-Sheng Feng; Guoqiang Chen; Jianxiu Yu
Journal:  Nat Commun       Date:  2012-06-19       Impact factor: 14.919

5.  The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression.

Authors:  Bin Liu; Samuel Tahk; Kathleen M Yee; Guoping Fan; Ke Shuai
Journal:  Science       Date:  2010-10-22       Impact factor: 47.728

Review 6.  Pharmacological treats for SUMO addicts.

Authors:  Marco P Licciardello; Stefan Kubicek
Journal:  Pharmacol Res       Date:  2016-01-24       Impact factor: 7.658

7.  SUMOylation regulates AKT1 activity.

Authors:  C F de la Cruz-Herrera; M Campagna; V Lang; J del Carmen González-Santamaría; L Marcos-Villar; M S Rodríguez; A Vidal; M Collado; C Rivas
Journal:  Oncogene       Date:  2014-04-07       Impact factor: 9.867

8.  SUMOylation of Myc-family proteins.

Authors:  Arianna Sabò; Mirko Doni; Bruno Amati
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

9.  Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks.

Authors:  Yaron Galanty; Rimma Belotserkovskaya; Julia Coates; Sophie Polo; Kyle M Miller; Stephen P Jackson
Journal:  Nature       Date:  2009-12-17       Impact factor: 49.962

10.  SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies.

Authors:  Ya-Chen Liang; Chia-Chin Lee; Ya-Li Yao; Chien-Chen Lai; M Lienhard Schmitz; Wen-Ming Yang
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

View more
  30 in total

Review 1.  Sumoylation in Physiology, Pathology and Therapy.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Cells       Date:  2022-02-26       Impact factor: 6.600

Review 2.  Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors.

Authors:  Lisa N Heppler; David A Frank
Journal:  Trends Cancer       Date:  2017-11-10

3.  Partition: a surjective mapping approach for dimensionality reduction.

Authors:  Joshua Millstein; Francesca Battaglin; Malcolm Barrett; Shu Cao; Wu Zhang; Sebastian Stintzing; Volker Heinemann; Heinz-Josef Lenz
Journal:  Bioinformatics       Date:  2020-02-01       Impact factor: 6.937

4.  PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial-mesenchymal transition.

Authors:  Ayan Chanda; Yoshiho Ikeuchi; Kunal Karve; Anusi Sarkar; Amrita Singh Chandhoke; Lili Deng; Azad Bonni; Shirin Bonni
Journal:  Cell Death Differ       Date:  2020-08-07       Impact factor: 15.828

Review 5.  Debulking of topoisomerase DNA-protein crosslinks (TOP-DPC) by the proteasome, non-proteasomal and non-proteolytic pathways.

Authors:  Yilun Sun; Liton Kumar Saha; Sourav Saha; Ukhyun Jo; Yves Pommier
Journal:  DNA Repair (Amst)       Date:  2020-07-10

6.  An in vitro Förster resonance energy transfer-based high-throughput screening assay identifies inhibitors of SUMOylation E2 Ubc9.

Authors:  Yu-Zhe Wang; Xiao Liu; George Way; Vipul Madarha; Qing-Tong Zhou; De-Hua Yang; Jia-Yu Liao; Ming-Wei Wang
Journal:  Acta Pharmacol Sin       Date:  2020-04-27       Impact factor: 7.169

Review 7.  Current Status of SUMOylation Inhibitors.

Authors:  Christopher M Brackett; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

8.  SUMOylation activates large tumour suppressor 1 to maintain the tissue homeostasis during Hippo signalling.

Authors:  Liu Mei; Meiyu Qv; Hangyang Bao; Qiangqiang He; Yana Xu; Qin Zhang; Wei Shi; Qianlei Ren; Ziyi Yan; Chengyun Xu; Chao Tang; Musaddique Hussain; Ling-Hui Zeng; Ximei Wu
Journal:  Oncogene       Date:  2021-07-15       Impact factor: 9.867

Review 9.  Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients.

Authors:  Helena Oliveres; David Pesántez; Joan Maurel
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

Review 10.  SUMOylation in development and neurodegeneration.

Authors:  Tak-Yu Yau; Oscar Molina; Albert J Courey
Journal:  Development       Date:  2020-03-18       Impact factor: 6.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.